| Garo H. Armen |
Garo H. Armen is the founder of Agenus, Inc. (founded in 1994) where he currently holds the title of Chairman & Chief Executive Officer. He is also the founder of Children of Armenia Fund (founded in 2002) where he currently serves as Chairman. Additionally, he is the founder of Protagenic Therapeutics, Inc. (founded in 1994) and holds the title of Executive Chairman. Dr. Armen's current job(s) include being the Chairman of MiNK Therapeutics, Inc. (since 2017), Director of Agenus UK Ltd., and Director of Agenus Switzerland, Inc.His former job(s) include being the Chairman of Elan Corp. Plc (from 2002 to 2004), Executive Chairman of Atrinsic, Inc., Director of Color Kinetics, Inc. (from 1998 to 2007), Director of Protagenic Therapeutics, Inc. (from 2009 to 2012), Director of ScrollMotion, Inc., and Managing General Partner of Armen Partners LP (from 1989 to 2009). He also held the position of Senior Vice President at Dean Witter Reynolds, Inc. (from 1986 to 1988) and was a Research Fellow at Brookhaven National Laboratory. He started his career as a First Vice President at E.F. Hutton & Co., Inc. (from 1981 to 1986). Dr. Armen's education includes a doctorate degree from City University of New York and an undergraduate degree from Queens College. |
| Robin G. Taylor |
Robin G. Taylor is currently the Chief Commercial Officer at Agenus, Inc. In 2019-2020, he held the same position at Seagen Inc. Taylor received his undergraduate degree from the University of British Columbia, his doctorate from the University of Toronto, and his MBA from the University of California, Berkeley. |
| Julie DeSander |
Julie DeSander is Chief Business Officer for Agenus, Inc.
Ms. DeSander received an MBA from MIT Sloan School of Management and a graduate degree from Harvard Mit Health Sciences & Technology. |
| Steven O’Day |
Steven O’Day currently works at Agenus, Inc., as Chief Medical Officer from 2021. Dr. O’Day also formerly worked at John Wayne Cancer Institute, as Executive Director. Dr. O’Day received his undergraduate degree from Williams College and doctorate degree from The Johns Hopkins University School of Medicine. |
| Alfred Dadson |
Alfred Dadson is currently the Chief Manufacturing Officer at Agenus, Inc. He previously worked as the Vice President-Manufacturing Operations at XOMA (US) LLC. |
| Eric Humes |
Eric Humes is currently the Chief Quality Officer at Agenus, Inc. He previously worked as a Senior Director-Quality Assurance at ICON plc from 2008 to 2009. He also served as a Director at The Society of Quality Assurance. Mr. Humes completed his undergraduate degree at the University of Maryland. |
| Tracy Mazza Clemente |
Tracy Mazza Clemente is currently the Chief People Officer at Agenus, Inc. She obtained an undergraduate degree from St. Mary's College of California. |
| Craig Winter |
Craig Winter was the founder of Teracom Networks, which was founded in 1992, where he held the title of President from 1992 to 2021. Currently, he is the Chief Information Officer at Agenus, Inc. Mr. Winter's education history includes an undergraduate degree from Albright College. |
| Robin E. Abrams |
Robin E. Abrams is currently the Chief Legal Officer at Agenus, Inc. and the Executive Vice President & General Counsel at vTv Therapeutics LLC. Previously, she worked as a Director at Lexy, Inc., Director at vTv Therapeutics, Inc., Chief Administrative Officer & General Counsel at SIGA Technologies, Inc., and Vice President & Associate General Counsel at Purdue Pharma LP. She received her undergraduate degree from Cornell University in 1986 and her graduate degree from New York University School of Law in 1989. |
| Homa Yeganegi |
Homa Yeganegi is currently the Chief Product Strategy Officer at Agenus, Inc. She previously worked as the Vice President-Global Scientific & Medical Affairs at Halozyme Therapeutics, Inc., Senior Vice President & Head-Medical Affairs at Turning Point Therapeutics, Inc., and Senior Vice President-Global Medical Affairs at Clovis Oncology, Inc. She has a graduate degree from The University of Western Australia and an undergraduate degree from the University of Tehran. |
| Nils Eckardt |
Nils Eckardt is currently the Chief Medical Affairs Officer at Agenus, Inc. |
| Allison M. Jeynes-Ellis |
Allison M. Jeynes-Ellis is currently the Chief Executive Officer at Avillion LLP since 2014. She is also an Independent Director at Agenus, Inc. since 2018. Additionally, she holds director positions at Siolta Therapeutics, Inc. and Anaveon AG. |
| Brian J. Corvese |
Brian J. Corvese is the founder of Vencor Capital (Pty) Ltd., which was founded in 1999. He is currently an Independent Director at Agenus, Inc. since 2007, a Director at National Telecommunications Corp., and an Independent Non-Executive Director at Protagenic Therapeutics, Inc. and MiNK Therapeutics, Inc. since 2017. Mr. Corvese's former positions include Managing Director & Partner at Soros Fund Management LLC, and Portfolio Manager & Partner at Chancellor Capital Management, Inc. from 1988 to 1996. He received his undergraduate degree from the University of Rhode Island. |
| Susan B. Hirsch |
Susan B. Hirsch is currently an Independent Director at Agenus, Inc. and a Director at Tecogen, Inc. She previously worked as a Managing Director at Teachers Advisors LLC, TIAA-CREF Investment Management LLC, Nuveen Investments, Inc., and Tiaa Large Cap Growth Fund. She also served as an Executive Vice President at Jennison Associates LLC and a Senior Manager-Portfolio at Delphi Asset Management Corp. Ms. Hirsch completed her undergraduate degree at Brooklyn College. |
| Ulf Arne Wiinberg |
Ulf Arne Wiinberg is currently the President & Chief Executive Officer at X-Vax Technology, Inc., Chairman & Chief Executive Officer at Ulf Wiinberg Consult & Invest AB, Chairman at Lund Science AB, Chairman at Sigrid Therapeutics AB, Independent Director at Agenus, Inc., Independent Director at UCB SA, Independent Director at Alfa Laval AB, Director at International Federation of Pharmaceutical Manufacturers, Director at European Federation of Pharmaceutical Industries & Assns, Director at Lexington Group, Inc., Director at Wallon Institute for Life Lead Sciences, Director at UCB Pharma AB, Independent Director at MiNK Therapeutics, Inc., and Director at AgenTus Therapeutics SA. He previously served as the President & Chief Executive Officer at H. Lundbeck A from 2008 to 2014, Chairman at Hansa Biopharma AB from 2016 to 2022, Chairman & Manager-Human Resources at Trialbee AB, Chairman at Avillion LLP, Director-Europe, Middle East & Africa Region at Wyeth Pharmaceuticals LLC, Managing Director at John Wyeth & Brother Ltd., Director at Pharmaceutical Research & Manufacturers of America, Director at The European Medicines Agency, Director at Nestle Health Science SA, President-Europe, Middle East & Africa Region at Wyeth LLC from 2002 to 2008, President at Wyeth Consumer Healthcare, Inc. from 2002 to 2005, and President at Wyeth BioPharma. |
